Analyst will focus on royalties defeat and increased costs in Genmab's Q1 report

When Genmab releases its first quarterly report later today, Sydbank analyst Søren Løntoft Hansen will search for news about the arbitration case the firm lost against Janssen and will keep an eye on expenses.
Photo: Joost Melis / Genmab / PR
Photo: Joost Melis / Genmab / PR
by marketwire, translated by daniel pedersen

Genmab’s cost developments and a lost arbitration case with its partner, Janssen, the pharmaceutical arm of Johnson & Johnson, will be the focus of the Danish biotech firm’s first quarterly report for 2022, which is slated to release later today, Wednesday, after trading closes in Denmark.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading